Table 1.
Cohort Description.
| Parameters | Value (Range) % [Proportion] |
|---|---|
| Median age at diagnosis (y) | 67 (29–94) |
| >60 | 69.1% [67/97] |
| Gender | |
| Male | 55.7% [54/97] |
| Female | 44.3% [43/97] |
| Median follow-up time (mo) | 41.1 (2–93, 95% CI, 29.0–53.6) |
| First-line therapy | |
| R-CHOP | 80.4% [78/97] |
| + Methotrexate | 9.3% [9/97] |
| R-CHOP like | 19.6% [19/97] |
| Mini R-CHOP | 8.2% [8/97] |
| R-CVP | 9.3% [9/97] |
| R-CHVP | 1.0% [1/97] |
| R-COP | 1.0% [1/97] |
| Complete response rate | 78.3% [76/97] |
| Overall response rate | 83.5% [81/97] |
| Primary refractory cases | 20.6% [20/97] |
| Relapse cases | 18.5% [18/97] |
| SOS | 24 mo: 70.3% (95% CI, 59.4–78.8) |
| 60 mo: 62.0% (95% CI, 49.4–72.4) | |
| 92 mo: 62.0% (95% CI, 49.4–72.4) | |
| PFS | 24 mo: 63.7% (95% CI, 52.9–72.7) |
| 60 mo: 55.7% (95% CI, 42.7–66.9) | |
| 92 mo: 51.1% (95% CI, 36.2–64.1) | |
| Ann Arbor staging classification (diagnosis) | |
| I (Single LN involves) | 11.3% [11/97] |
| II (2 or more LN ipsilateral to the diaphragm) | 20.6% [20/97] |
| III (LN on both sides of the diaphragm) | 21.6% [21/97] |
| IV (involvement extralymphatic organs or tissues) | 46.4% [45/97] |
| LDH > upper limit of normal | 75.0% [73/97] |
| R-IPI class (diagnosis) | |
| Very low risk: 0 | 7.2% [7/97] |
| Low risk: 1–2 | 44.3% [43/97] |
| High risk: 3–5 | 48.5% [47/97] |
| DLBCL subtype (Hans’ algorithm) | |
| GC | 37.1% [36/97] |
| Non-GC | 62.9% [61/97] |
| Genetics | |
| High grade B-cell lymphoma (double/triple hits) | 3.1% [3/97] |
| MYC rearrangements | 9.0% [8/89] |
| Including MYC-Ig | 4.5% [4/89] |
| CYCLON (IHC pattern) | |
| Negative | 7.2% [7/97] |
| Pan-nuclear | 61.9% [60/97] |
| Nucleolar | 12.4% [12/97] |
| Extranucleolar | 18.6% [18/97] |
DLBCL = diffuse large B-cell lymphoma; GC = germinal center; IHC = immunohistochemistry; LDH = lactate dehydrogenase; LN = lymph node; MYC-Ig = gene rearrangement involving MYC and Immunoglobulin loci; PFS = progression-free survival; R-CHOP = rituximab-cyclophosphamide, hydroxydaunorubicine, oncovin, prednisone; R-CHVP = rituximab-cyclophosphamide, hydroxydaunorubicine, vincristine, prednisone; R-COP = rituximab-cyclophosphamide, oncovin, prednisone; R-CVP = rituximab-cyclophosphamide, vincristine, prednisone; R-IPI = revised version of the International Prognostic Index; SOS = specific overall survival.